An Analysis of the FALCON Trial
Matthew J. Ellis, MD, PhD, discusses the ongoing phase III FALCON trial.
Matthew J. Ellis, MD, PhD, professor, Department of Medicine, Oncology Division, Breast Oncology Section, Washington University School of Medicine in St. Louis, Missouri and the Siteman Cancer Center, discusses the ongoing phase III FALCON trial.
Clinical Pearls
- The FALCON trial is comparing anastrozole to the newly approved, high-dose fulvestrant (500mg) for patients with treatment-naïve metastatic breast cancer
- The rationale of the trial is to see if the high dose of fulvestrant will maintain disease control for a longer period of time than patients receiving anastrozole
- This is a registration trial and will alter the label of fulvestrant to include treatment-naïve advanced breast cancer
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Rugo Surveys Peers on Treatment After Metastatic Relapse of HR+, HER2– Breast Cancer
April 20th 2024During a Case-Based Roundtable® event, Hope S. Rugo, MD, FASCO, moderated a discussion on treatment options for a patient whose breast cancer recurred several years after adjuvant therapy.
Read More
